Analyst firms · Raymond James · EW

Raymond James EW price target and rating history

Edwards Lifesciences Corporation (EW) · Health Care

Raymond James rates Edwards Lifesciences Corporation (EW) Outperform with a $96 price target, as of its latest action on Nov 3, 2025. It has published 6 rating actions on EW since August 2021, including 1 upgrade and 1 downgrade. Across 7 firms with a EW price target in the last 12 months, the median target is $110.

Current rating
Outperform
Price target
$96
Median target, all firms
$110
Actions on EW
6

Raymond James price target on EW

$134$115$9620222023202420252026
Raymond James price target on EW, each point a stated target, August 2021 to November 2025.

Every Raymond James rating on EW

How other firms rate EW

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Robert W. BairdOutperform$116Nov 5, 2026
Truist SecuritiesBuy$113Nov 4, 2026
BarclaysOverweight$110Oct 7, 2026
UBSBuy$110Jul 28, 2026
Leerink PartnersOutperform$101Jul 24, 2026
Wolfe ResearchOutperform$92Apr 1, 2026
TD CowenBuy$97Jan 9, 2026

Questions about Raymond James and EW

What is Raymond James's price target for EW?
Raymond James's latest stated price target for Edwards Lifesciences Corporation (EW) is $96, from its action on Nov 3, 2025.
What is Raymond James's rating on EW?
Raymond James rates EW Outperform, a bullish rating, as of Nov 3, 2025.
When did Raymond James last change its view on EW?
On Nov 3, 2025, Raymond James upgrades to Outperform from Mkt Perform, price target $96.
How does Raymond James's EW target compare with other analysts?
Across 7 firms with a EW price target in the last 12 months, the median target is $110.

More EW rating histories

All Raymond James ratingsEW news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.